{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:39:02Z","timestamp":1793497142364,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2019T045"],"award-info":[{"award-number":["2019T045"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2019T045"],"award-info":[{"award-number":["2019T045"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/18\/5033837"],"award-info":[{"award-number":["PG\/18\/5033837"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/22\/10989"],"award-info":[{"award-number":["PG\/22\/10989"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure (HF) clustering typically relies on clinical characteristics which may not reflect underlying pathophysiology relevant for personalized medicine. We aimed to identify plasma protein profiles of HF patients with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using latent class analysis, we derived clusters based on 1) clinical characteristics, and 2) proteomics (SomaScan) from 379 HFrEF patients (median age 64 years [Q1 56; Q3 72], 73% male). Survival analysis assessed associations with major cardiovascular (CV) events (HF hospitalization, CV death, or advanced therapy), HF hospitalization, CV death, and all-cause mortality. Associations were validated in 511 external patients (median age 72 years [Q1 63; Q3 79], 70% male). We identified differentially expressed proteins and explored whether proteins are targets of developmental or approved drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We show that clinical clustering identifies three patient clusters without distinct disease progression. Contrary to this, clustering based on plasma\u00a0proteomics identifies three patient\u00a0clusters with clear differences in disease, which are\u00a0validated in the external cohort. The slowly progressing cluster 1 includes younger patients with fewer comorbidities, while the rapidly progressing cluster 3 consists of\u00a0older patients with more atrial fibrillation and renal failure, and the hospitalization cluster 2 is intermediate\u00a0in many characteristics. Medication use is similar across clusters. Relative to cluster 1, patients in\u00a0cluster 2 have an increased risk of major CV events (HR 2.31, 95%CI 1.23; 4.36) and HF hospitalization (HR 2.30, 95%CI 1.10; 4.78). Patients in cluster 3 experienced increased\u00a0 event rates\u00a0of major CV events (HR 5.84), HF hospitalization (6.50), CV death (8.58), and all-cause mortality (5.07). Twelve proteins are differentially expressed\u00a0across the identified clusters, including druggable CD2, GDF-15, ABO, IGFBP-1, IGFBP-2, and RNase1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Proteomics-based clustering identifies three HFrEF clusters associated with distinct outcomes that remain undetected using only clinical characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01213-x","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:05:30Z","timestamp":1763665530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Proteomics-based clustering outperforms clinical clustering in identifying people with heart failure with distinct outcomes"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-1989","authenticated-orcid":false,"given":"Marion","family":"van Vugt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicong","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-9931","authenticated-orcid":false,"given":"Teun B.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-2805","authenticated-orcid":false,"given":"Marie","family":"de Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martijn","family":"Akkerhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-9261","authenticated-orcid":false,"given":"Kadir","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-7741","authenticated-orcid":false,"given":"Alicia","family":"Uijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Rizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor AWM","family":"Umans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Lanfear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-7510","authenticated-orcid":false,"given":"Jessica","family":"van Setten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-0424","authenticated-orcid":false,"given":"A. Floriaan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1001\/jama.2013.1063","volume":"309","author":"J Butler","year":"2013","unstructured":"Butler, J., Fonarow, G. C. & Gheorghiade, M. Strategies and opportunities for drug development in heart failure. JAMA 309, 1593\u20131594 (2013).","journal-title":"JAMA"},{"key":"1213_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrcardio.2012.181","volume":"10","author":"M Vaduganathan","year":"2013","unstructured":"Vaduganathan, M., Greene, S. J., Ambrosy, A. P., Gheorghiade, M. & Butler, J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat. Rev. Cardiol. 10, 85\u201397 (2013).","journal-title":"Nat. Rev. Cardiol."},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2014.07.979","volume":"64","author":"T Ahmad","year":"2014","unstructured":"Ahmad, T. et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J. Am. Coll. Cardiol. 64, 1765\u20131774 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1213_CR5","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","volume":"50","author":"LB Daniels","year":"2007","unstructured":"Daniels, L. B. & Maisel, A. S. Natriuretic peptides. J. Am. Coll. Cardiol. 50, 2357\u20132368 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1213_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2022.06.020","volume":"364","author":"I de Lange","year":"2022","unstructured":"de Lange, I. et al. Heart failure subphenotypes based on repeated biomarker measurements are associated with clinical characteristics and adverse events (Bio-SHiFT study). Int. J. Cardiol. 364, 77\u201384 (2022).","journal-title":"Int. J. Cardiol."},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1093\/eurheartj\/ehy712","volume":"39","author":"J Tromp","year":"2018","unstructured":"Tromp, J. et al. Novel endotypes in heart failure: effects on guideline-directed medical therapy. Eur. Heart J. 39, 4269\u20134276 (2018).","journal-title":"Eur. Heart J."},{"key":"1213_CR8","doi-asserted-by":"crossref","unstructured":"Petersen, T. B. et al. HFrEF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms. eBioMedicine 93,1-15 (2023).","DOI":"10.1016\/j.ebiom.2023.104655"},{"key":"1213_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ahj.2017.10.008","volume":"196","author":"N van Boven","year":"2018","unstructured":"van Boven, N. et al. Toward personalized risk assessment in patients with chronic heart failure: detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. Am. Heart J. 196, 36\u201348 (2018).","journal-title":"Am. Heart J."},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jchf.2017.07.009","volume":"5","author":"DE Lanfear","year":"2017","unstructured":"Lanfear, D. E. et al. Targeted metabolomic profiling of plasma and survival in heart failure patients. JACC Heart Fail. 5, 823\u2013832 (2017).","journal-title":"JACC Heart Fail."},{"key":"1213_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.007012","volume":"13","author":"DE Lanfear","year":"2020","unstructured":"Lanfear, D. E. et al. Polygenic score for \u03b2-blocker survival benefit in European ancestry patients with reduced ejection fraction heart failure. Circ. Heart Fail. 13, e007012 (2020).","journal-title":"Circ. Heart Fail."},{"key":"1213_CR12","unstructured":"Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. Nat. Preced. 5, 1\u201317 (2010)."},{"key":"1213_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","volume":"25","author":"SA Williams","year":"2019","unstructured":"Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851\u20131857 (2019).","journal-title":"Nat. Med."},{"key":"1213_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011208","volume":"18","author":"J Chadwick","year":"2025","unstructured":"Chadwick, J. et al. Harnessing the plasma proteome to predict mortality in heart failure subpopulations. Circ. Heart Fail. 18, e011208 (2025).","journal-title":"Circ. Heart Fail."},{"key":"1213_CR15","doi-asserted-by":"crossref","unstructured":"Fop, M., Smart, K. & Murphy, T. B. Variable selection for latent class analysis with application to low back pain diagnosis. Ann. Appl. Stat. 11, 2080\u20132110 (2017).","DOI":"10.1214\/17-AOAS1061"},{"key":"1213_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v053.i04","volume":"53","author":"LGA Scrucca","year":"2013","unstructured":"Scrucca, L. G. A. A package for genetic algorithms in R. J. Stat. Softw. 53, 1\u201337 (2013).","journal-title":"J. Stat. Softw."},{"key":"1213_CR17","doi-asserted-by":"crossref","unstructured":"Nylund, K. L., Asparouhov, T. & Muth\u00e9n, B. O. Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. Struct. Equ. Model. 14, 535\u2013569 (2007).","DOI":"10.1080\/10705510701575396"},{"key":"1213_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9, eaag1166 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez, D. et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 47, D930\u2013D940 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1213_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13690-5","volume":"11","author":"S Shah","year":"2020","unstructured":"Shah, S. et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat. Commun. 11, 1\u201312 (2020).","journal-title":"Nat. Commun."},{"key":"1213_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415\u20131424 (2021).","journal-title":"Nat. Genet."},{"key":"1213_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34216-6","volume":"13","author":"MG Levin","year":"2022","unstructured":"Levin, M. G. et al. Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. Nat. Commun. 13, 6914 (2022).","journal-title":"Nat. Commun."},{"key":"1213_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39253-3","volume":"14","author":"D Rasooly","year":"2023","unstructured":"Rasooly, D. et al. Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure. Nat. Commun. 14, 3826 (2023).","journal-title":"Nat. Commun."},{"key":"1213_CR24","doi-asserted-by":"crossref","unstructured":"The CARDIoGRAMplusC4D Consortium. A comprehensive 1000 Genomes\u2013based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47, 1121\u20131130 (2015).","DOI":"10.1038\/ng.3396"},{"key":"1213_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/eurheartj\/ehaa1040","volume":"42","author":"JA Hartiala","year":"2021","unstructured":"Hartiala, J. A. et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. Eur. Heart J. 42, 919\u2013933 (2021).","journal-title":"Eur. Heart J."},{"key":"1213_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(10)61996-4","volume":"377","author":"MP Reilly","year":"2011","unstructured":"Reilly, M. P. et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377, 383\u2013392 (2011).","journal-title":"Lancet"},{"key":"1213_CR27","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/ng.3708","volume":"48","author":"RN Eppinga","year":"2016","unstructured":"Eppinga, R. N. et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat. Genet. 48, 1557\u20131563 (2016).","journal-title":"Nat. Genet."},{"key":"1213_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04148-1","volume":"9","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez, J. et al. Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system. Nat. Commun. 9, 1947 (2018).","journal-title":"Nat. Commun."},{"key":"1213_CR29","unstructured":"Harper A. R. et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 53 https:\/\/www.nature.com\/articles\/s41588-020-00764-0 (2021)."},{"key":"1213_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65667-0","volume":"14","author":"K Andrzejczyk","year":"2024","unstructured":"Andrzejczyk, K. et al. Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum. Sci. Rep. 14, 14871 (2024).","journal-title":"Sci. Rep."},{"key":"1213_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-015-0149-z","volume":"7","author":"A Maciejak","year":"2015","unstructured":"Maciejak, A. et al. Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med. 7, 1\u201315 (2015).","journal-title":"Genome Med."},{"key":"1213_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-2002-23198","volume":"34","author":"M Harrela","year":"2002","unstructured":"Harrela, M. et al. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm. Metab. Res. 34, 144\u2013149 (2002).","journal-title":"Horm. Metab. Res."},{"key":"1213_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2008.08.003","volume":"138","author":"I Janszky","year":"2010","unstructured":"Janszky, I., Hallqvist, J., Ljung, R. & Hammar, N. Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls. Int. J. Cardiol. 138, 50\u201355 (2010).","journal-title":"Int. J. Cardiol."},{"key":"1213_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCGENETICS.113.000490","volume":"8","author":"SA Halim","year":"2015","unstructured":"Halim, S. A. et al. Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events. Circ. Cardiovasc. Genet. 8, 168\u2013177 (2015).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"1213_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fendo.2018.00388","volume":"9","author":"A Hoeflich","year":"2018","unstructured":"Hoeflich, A., David, R. & Hjortebjerg, R. Current IGFBP-related biomarker research in cardiovascular disease\u2014we need more structural and functional information in clinical studies. Front. Endocrinol. 9, 388 (2018).","journal-title":"Front. Endocrinol."},{"key":"1213_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11897-023-00610-4","volume":"20","author":"K Sawalha","year":"2023","unstructured":"Sawalha, K., Norgard, N. B., Drees, B. M. & L\u00f3pez-Candales, A. Growth differentiation factor 15 (GDF-15), a new biomarker in heart failure management. Curr. Heart Fail. Rep. 20, 287\u2013299 (2023).","journal-title":"Curr. Heart Fail. Rep."},{"key":"1213_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140\u2013151 (2017).","journal-title":"Clin. Chem."},{"key":"1213_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.431","volume":"18","author":"MM Chan","year":"2016","unstructured":"Chan, M. M. et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 18, 81\u201388 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"1213_CR39","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf, T. et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054\u20131060 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1213_CR40","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","volume":"68","author":"MR Zile","year":"2016","unstructured":"Zile, M. R. et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J. Am. Coll. Cardiol. 68, 2425\u20132436 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1213_CR41","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","volume":"107","author":"IS Anand","year":"2003","unstructured":"Anand, I. S. et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278\u20131283 (2003).","journal-title":"Circulation"},{"key":"1213_CR42","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.ehj.2003.07.005","volume":"24","author":"R Gardner","year":"2003","unstructured":"Gardner, R., \u00d6zalp, Murday, F., Robb, A. & McDonagh, S. T. N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24, 1735\u20131743 (2003).","journal-title":"Eur. Heart J."},{"key":"1213_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","volume":"23","author":"A Uijl","year":"2021","unstructured":"Uijl, A. et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 23, 973\u2013982 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"1213_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","volume":"9","author":"JE Ho","year":"2016","unstructured":"Ho, J. E. et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ. Heart Fail. 9, e003116 (2016).","journal-title":"Circ. Heart Fail."},{"key":"1213_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jchf.2019.03.011","volume":"7","author":"D Stolfo","year":"2019","unstructured":"Stolfo, D., et al. Sex-based differences in heart failure across the ejection fraction spectrum phenotyping, and prognostic and therapeutic implications. JACC Heart Fail. 7, 505\u2013515 (2019).","journal-title":"JACC Heart Fail."},{"key":"1213_CR46","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","volume":"40","author":"CS Lam","year":"2019","unstructured":"Lam, C. S. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859\u20133868c (2019).","journal-title":"Eur. Heart J."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01213-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:16:07Z","timestamp":1764591367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01213-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01213-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.C.M. has served on advisory boards of Abbott, Astra Zeneca, Boehringer Ingelheim, and Novartis. A.F.S. has received funding from New Amsterdam and Servier for unrelated work and is an Editorial Board Member for Communications Medicine but was not involved in the editorial review or peer review, nor in the decision to publish this article. I.K. has received travel reimbursement from SomaLogic and Olink. D.E.L. is a consultant for Astra Zeneca, Bayer, Cytokinetics, Illumina, RyCarma, has participated in research with Akros, AstraZeneca, Cytokinetics, Lilly, Kardigan, Novartis, Pfizer, Somalogic, and has a patent (held by Henry Ford Health) for a beta\u2010blocker response polygenic score. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}